Coexpression cluster:C266

Full id: C266_acute_chronic_leukemia_small_choriocarcinoma_hepatoma_Mast

Phase1 CAGE Peaks

Hg19::chr10:126826943..126826984,-	p28@CTBP2
Hg19::chr10:127505042..127505063,-	p8@UROS
Hg19::chr10:25820836..25820845,+	p@chr10:25820836..25820845 +
Hg19::chr10:25820884..25820895,+	p@chr10:25820884..25820895 +
Hg19::chr10:25820904..25820913,+	p@chr10:25820904..25820913 +
Hg19::chr10:25821044..25821091,+	p@chr10:25821044..25821091 +
Hg19::chr11:33914678..33914683,-	p@chr11:33914678..33914683 -
Hg19::chr11:74807933..74807937,-	p@chr11:74807933..74807937 -
Hg19::chr12:115758751..115758760,-	p@chr12:115758751..115758760 -
Hg19::chr12:115758858..115758876,-	p@chr12:115758858..115758876 -
Hg19::chr12:115758891..115758908,-	p@chr12:115758891..115758908 -
Hg19::chr12:71617078..71617086,-	p@chr12:71617078..71617086 -
Hg19::chr12:78870953..78870955,+	p@chr12:78870953..78870955 +
Hg19::chr14:105166013..105166017,+	p@chr14:105166013..105166017 +
Hg19::chr14:67859531..67859537,-	p9@PLEK2
Hg19::chr16:24124312..24124336,+	p@chr16:24124312..24124336 +
Hg19::chr16:24127820..24127835,-	p@chr16:24127820..24127835 -
Hg19::chr16:88558406..88558427,+	p@chr16:88558406..88558427 +
Hg19::chr16:88858526..88858538,-	p@chr16:88858526..88858538 -
Hg19::chr17:25899255..25899265,+	p@chr17:25899255..25899265 +
Hg19::chr17:72864739..72864767,-	p5@FDXR
Hg19::chr18:31319109..31319114,+	p9@ASXL3
Hg19::chr18:43620002..43620017,-	p@chr18:43620002..43620017 -
Hg19::chr19:51105300..51105305,+	p@chr19:51105300..51105305 +
Hg19::chr19:5131212..5131221,+	p4@KDM4B
Hg19::chr19:5131887..5131896,+	p@chr19:5131887..5131896 +
Hg19::chr19:59067834..59067852,-	p@chr19:59067834..59067852 -
Hg19::chr1:159253361..159253368,+	p@chr1:159253361..159253368 +
Hg19::chr1:176849256..176849268,+	p@chr1:176849256..176849268 +
Hg19::chr1:179011968..179011976,-	p@chr1:179011968..179011976 -
Hg19::chr22:36007795..36007820,-	p@chr22:36007795..36007820 -
Hg19::chr2:219258788..219258830,+	p@chr2:219258788..219258830 +
Hg19::chr2:220386017..220386029,+	p@chr2:220386017..220386029 +
Hg19::chr2:225249514..225249517,-	p@chr2:225249514..225249517 -
Hg19::chr2:5211564..5211614,+	p@chr2:5211564..5211614 +
Hg19::chr3:139059704..139059754,-	p@chr3:139059704..139059754 -
Hg19::chr3:50211282..50211296,+	p@chr3:50211282..50211296 +
Hg19::chr3:52334122..52334129,-	p@chr3:52334122..52334129 -
Hg19::chr3:52334165..52334173,-	p@chr3:52334165..52334173 -
Hg19::chr4:124087446..124087458,+	p@chr4:124087446..124087458 +
Hg19::chr4:134160987..134160994,-	p@chr4:134160987..134160994 -
Hg19::chr4:171901111..171901116,+	p@chr4:171901111..171901116 +
Hg19::chr5:1201575..1201595,+	p3@SLC6A19
Hg19::chr5:1201599..1201625,+	p2@SLC6A19
Hg19::chr6:31615512..31615544,-	p@chr6:31615512..31615544 -
Hg19::chr6:42072634..42072643,-	p13@C6orf132
Hg19::chrX:11327532..11327554,-	p@chrX:11327532..11327554 -
Hg19::chrX:48559008..48559045,-	p@chrX:48559008..48559045 -
Hg19::chrX:48650688..48650735,+	p5@GATA1

Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

---

No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data

---

GO ID	GO name	FDR corrected p-value
GO:0016730	oxidoreductase activity, acting on iron-sulfur proteins as donors	0.00715294948781349
GO:0004324	ferredoxin-NADP+ reductase activity	0.00715294948781349
GO:0008937	ferredoxin reductase activity	0.00715294948781349
GO:0016731	oxidoreductase activity, acting on iron-sulfur proteins as donors, NAD or NADP as acceptor	0.00715294948781349
GO:0046502	uroporphyrinogen III metabolic process	0.00953656411554144
GO:0006780	uroporphyrinogen III biosynthetic process	0.00953656411554144
GO:0004852	uroporphyrinogen-III synthase activity	0.0163459895047015
GO:0015804	neutral amino acid transport	0.0485828177802072
GO:0006783	heme biosynthetic process	0.0485828177802072
GO:0015175	neutral amino acid transmembrane transporter activity	0.0485828177802072

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>

---

Cell Type

Ontology term	p-value	n
myeloid cell	5.43e-27	112
common myeloid progenitor	5.43e-27	112
hematopoietic cell	9.75e-25	182
hematopoietic stem cell	1.07e-24	172
angioblastic mesenchymal cell	1.07e-24	172
hematopoietic oligopotent progenitor cell	3.66e-24	165
hematopoietic multipotent progenitor cell	3.66e-24	165
myeloid lineage restricted progenitor cell	6.16e-15	70
granulocyte monocyte progenitor cell	6.21e-15	71
hematopoietic lineage restricted progenitor cell	3.67e-13	124
myeloid leukocyte	1.33e-12	76
macrophage dendritic cell progenitor	4.97e-12	65
monopoietic cell	1.85e-11	63
monocyte	1.85e-11	63
monoblast	1.85e-11	63
promonocyte	1.85e-11	63
leukocyte	2.44e-11	140
nongranular leukocyte	2.84e-10	119
classical monocyte	3.75e-09	45
CD14-positive, CD16-negative classical monocyte	5.94e-08	42

Uber Anatomy

Ontology term	p-value	n
hematopoietic system	5.05e-19	102
blood island	5.05e-19	102
hemolymphoid system	2.40e-16	112
bone marrow	6.54e-14	80
bone element	1.34e-12	86
skeletal element	2.35e-10	101
skeletal system	2.35e-10	101
immune system	1.69e-08	115

Disease

Ontology term	p-value	n
leukemia	6.41e-19	39
myeloid leukemia	3.70e-18	31
hematologic cancer	1.30e-17	51
immune system cancer	1.30e-17	51

Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

---

Novel motifs

JASPAR motifs

Motifs	-log10(p-value)
{{{tfbs_overrepresentation_jaspar}}}

ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data

---

No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data

---

"{{{coexpression_dpi_cluster_scores_median}}}" is not a number.